Videos

This interview with Amy Paller, MD, highlights the significance of the approval of ruxolitinib for the treatment of pediatric atopic dermatitis.

In this interview at EADV, Pasumarthi highlights her team’s late-breaking data on ritlecitinib’s use among patients with cicatricial alopecias.

This interview segment highlights Song’s risankizumab data covered during the 2025 EADV Congress in Paris.

Harrington and Desai weigh in with their thoughts on the bumetanide approval and how we can continue to battle edema in heart failure.

Saggese explains the importance of effective communication in MASH management and emphasizes the need for more therapies to offer patients.

A recent study reveals diverse real-world data on abrocitinib use for atopic dermatitis.

Eingun James Song, MD, highlights recent phase 4 data on risankizumab for patients with moderate to severe scalp and genital psoriasis.

Shawn Kwatra, MD, highlights his team’s findings presented at EADV on the efficacy of dupilumab in treating prurigo nodularis.

Brogan discusses the various opportunities and challenges that have accompanied recent evolutions in inflammatory bowel disease management.

Stewart reviews clinical pearls for performing rectal exams and explains common mistakes and misdiagnoses as well as how to avoid them.

Moore discusses the importance of individualizing PBC treatment now that multiple second-line therapies are available.

Real-world data show epinephrine nasal spray achieved an 89.2% success rate in treating anaphylaxis, nearly identical to the injection’s response rate.

This episode highlights the challenges of navigating demanding medical careers while raising young children, with insights and practical strategies.

Akin discussed updated data on elenestinib from the HARBOR trial in indolent systemic mastocytosis.

These interviews with Chovatiya and Stein Gold highlight a variety of key points from the dermatology-centric EADV Congress 2025 meeting in Paris, France.

Gandhi describes the crucial role APPs play in GI bleeding care and the importance of collaborative management of these patients.

Ugras describes recent evolutions in EoE, including new FDA-approved therapies, updated clinical guidelines, and better understanding of its pathophysiology.

Garimella describes recent progress in renal xenotransplantation, uncertainties that still need to be addressed, and how he sees it impacting the field moving forward.

Saggese describes recent evolutions in MASH care with the FDA approval of semaglutide and the continued importance of diet, physical activity, and weight management.

Brogan explains how to navigate the complexities of the Crohn’s disease treatment landscape and why patients need to be included in the decision making process.

In the final segment of this 7-part HCPLive Special Report, experts discuss the recently released ASPC/HFSA heart failure prevention statement.

In part 6 of this 7-part HCPLive Special Report, experts discuss the recently released ASPC/HFSA heart failure prevention statement.

In part 5 of this 7-part HCPLive Special Report, experts discuss the recently released ASPC/HFSA heart failure prevention statement.

In part 4 of this 7-part HCPLive Special Report, experts discuss the recently released ASPC/HFSA heart failure prevention statement.

In part 3 of this 7-part HCPLive Special Report, experts discuss the recently released ASPC/HFSA heart failure prevention statement.

In part 2 of this 7-part HCPLive Special Report, experts discuss the recently released ASPC/HFSA heart failure prevention statement.

In part 1 of this 7-part HCPLive Special Report, experts discuss the recently released ASPC/HFSA heart failure prevention statement.

McCarty explains progress made with new screening options but emphasizes ongoing barriers hindering screening goals and how they need to be addressed.